Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · IEX Real-Time Price · USD
7.66
+0.27 (3.65%)
At close: Mar 28, 2024, 4:00 PM
7.75
+0.09 (1.17%)
After-hours: Mar 28, 2024, 7:29 PM EDT

Inozyme Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Selling, General & Admin
20.820.8318.9310.554.593.49
Research & Development
54.8547.8537.7246.4916.228.1
Operating Expenses
75.6568.6856.6557.0420.8111.59
Operating Income
-75.65-68.68-56.65-57.04-20.81-11.59
Interest Expense / Income
3.330.260000
Other Expense / Income
-7.81-1.88-0.02-0.62-1.08-4.63
Pretax Income
-71.17-67.06-56.62-56.42-19.72-6.96
Net Income
-71.17-67.06-56.62-56.42-19.72-6.96
Shares Outstanding (Basic)
5238241111
Shares Outstanding (Diluted)
5238241111
Shares Change
37.27%60.30%113.46%832.81%12.60%-
EPS (Basic)
-1.37-1.78-2.40-5.11-16.67-6.63
EPS (Diluted)
-1.37-1.78-2.40-5.11-16.67-6.63
Free Cash Flow
-70.97-58.17-48.55-36.54-18.95-9.7
Free Cash Flow Per Share
-1.37-1.54-2.06-3.31-16.02-9.23
EBITDA
-66.51-65.62-55.57-56.21-19.64-6.94
Depreciation & Amortization
1.331.181.050.220.080.03
EBIT
-67.84-66.8-56.62-56.42-19.72-6.96
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).